3SBio Announces Strong 2026 Results and Global Expansion Efforts

3S Bio, a biopharmaceutical company based in China, has reported its interim results for the first half of 2026. The company recorded revenue of RMB 4.53 billion, marking a 3.9% year-over-year growth. Net profit attributable to equity holders reached RMB 1.15 billion, with adjusted operating net profit at RMB 1.44 billion, up by 26.5% year-over-year. Notably, R&D expenses increased by 24.9% year-over-year, totaling RMB 680 million. With financial resources amounting to RMB 19.4 billion, 3S Bio is well-positioned for further R&D investments and strategic initiatives. During the first half of the year, 3S Bio secured marketing approvals for core products…